摘要
糖尿病目前已经成为威胁人类健康的最主要的非传染性疾病之一,药物治疗是主要手段之一。钠-葡萄糖协同转运蛋白2抑制剂(SGLT-2i)是一种新型降糖药物,主要通过抑制近端肾小管SGLT-2的活性,降低肾小管对葡萄糖的重吸收,增加尿中葡萄糖的排泄,从而降低血糖,且安全性较好,因此受到广泛关注。本文就SGLT-2i在糖尿病治疗方面的临床研究情况进行综述,为临床医师用药提供参考。
Diabetes mellitus has become one of the most important non-communicable diseases that threaten human health.Drug treatment is one of the main methods.Sodium-glucose co-transporter 2 inhibitors(SGLT-2 i),a new kind of oral anti-diabetic drug,it inhibits the activity of proximal renal tubule SGLT-2,suppresses re-absorption of glucose in renal tubule,increases excretion of glucose in urine,and reduces blood glucose.SGLT-2 i has attracted wide attention because of its effectiveness and safety.This article reviews the clinical research of SGLT-2 i in the treatment of diabetes,in order to provide reference for clinician.
作者
张恒艳
胡小磊
ZHANG Heng-yan(Endocrinology department,the first affiliated hospital of Bengbu medical college,Bengbu,Anhui,233000,China)
出处
《齐齐哈尔医学院学报》
2019年第14期1784-1786,共3页
Journal of Qiqihar Medical University
基金
国家自然科学基金(81770803)
蚌埠医学院科技发展基金(BYKF1832)
关键词
钠-葡萄糖协同转运蛋白2抑制剂
糖尿病
Sodium-glucose co-transporter 2 inhibitor
Diabetes
Clinical research
